Starpharma Holdings Ltd (ASX: SPL) Share Price and News

Mr Thomas has a strong background in financial services and capital markets and is a non executive director of several Australian listed companies. He was previously a Partner of Potter, where he was also Head of Research. He is the former Chief Executive Officer (CEO) of County NatWest Securities and then became CEO and then Chairman of Citibank Corporate and Investment Bank in Australia. He is also Chair of AusBio Ltd, Grahger Investments, Chair of the State Library of NSW Foundation and a director of O Connell Street Associates. He has expertise in Mergers & Acquisition (M&A) and capital markets including advising on the floats of Commonwealth Bank of Australia and Qantas, and experience in Audit and Risk Management. He is also approved under the NSW prequalification scheme for Audit and Risk Committee Independent Chairs and Members for government/public sector agencies and has previously served as the Chairman of the Audit and Risk Committee of Virgin Australia Limited, HeartWare International Inc, REVA Medical Limited and the State Library of NSW. He is Member of Risk Committee.

Ms Maley has over 25 years of experience in the pharmaceutical industry, including 20 years in leadership roles at well known and leading organisations, including Novartis and AbbVie. Her previous roles include nine years at Novartis in senior commercial and executive roles and various sales and marketing positions with AbbVie/Abbott, Servier Laboratories, and Wyeth Pharmaceuticals. She has experience leading pharmaceutical innovation, marketing strategies, and business growth across Australia, Asia, and international markets. During her nine year career at Novartis, she held senior leadership positions, responsible for new products, commercialisation, strategy, and reimbursement matters. She also held General Management roles in both the Philippines and Australia. Prior to joining Starpharma, she was Acting CEO and Strategic Advisor at Biointelect, a firm specialising in strategic planning and commercialisation for the biopharmaceutical and medical device sector. She holds a board position at Neuroscience Research Australia.

Mr McIntyre has more than 20 years of executive experience including 18 years in the life sciences sector, having held various C suite level roles at Anthos Therapeutics, Inc., Tessa Therapeutics, Inc., AVITA Therapeutics, Inc., HeartWare International, Inc., and Braeburn, Inc. His experience also includes seven years as a Partner at Apple Tree Partners. During this time, he served as a non executive director of several US life science companies. Prior to entering life sciences, Mr McIntyre practiced as a senior attorney at Baker McKenzie and KPMG specialising in M&A, initial public offerings, and corporate law and also held various senior finance roles in both multinational companies and small growth companies. He is Chair of the Risk Committee.

Ms Cheng has a strong background in corporate finance and operational management with more than 30 years of experience including 20 years at Visy Industries/Pratt Holdings and 10 years in investment banking. She is currently Director of Corporate Development and Mergers & Acquisitions at Visy Industries / Pratt Holdings and has held various other senior executive team roles in the group including CFO. She has served as a non executive director of Export Finance Australia, a member of the Australian Governments International Development Policy Expert Panel, the Deputy Chair and Chair of the Finance, Audit and Risk committee of South East Water and a non executive member of the board at JRJJ Capital, the parent company of Merricks Capital, in an observer/advisory capacity. She is member of the Risk Committee.

Dr Davies has over 35 years of biopharmaceutical industry experience, including senior executive roles at CSL. His positions at CSL included Executive Vice President & General Manager, Asia Pacific, where he had full P&L responsibility across pharmaceuticals, plasma, vaccines, and diagnostics in Australia, New Zealand, China, and the broader Asia Pacific. As Global Head of Plasma Product R&D at CSL Behring, he led development of key products, notably the multi-billion-dollar immunoglobulin therapy, Privigen. He is a founding director of the Centre for Biopharmaceutical Excellence, a pharmaceutical consulting firm, and CBE Pure Solutions, a specialist provider of sterile fill finish and microbiological testing services. He has held numerous advisory and board roles, including with the Pharmaceutical Industry Council, Australian Red Cross, and Medicines Australia.

Dr Basser is a former corporate executive with over 30 years of international medical and biopharmaceutical experience, including 21 years at CSL. He has substantial expertise in international drug and vaccine development, having held multiple senior executive roles at CSL, including Senior Vice President (SVP) of Research and Development at CSL Seqirus; Chief Medical Officer at CSL Limited/CSL Behring; and SVP of Global Clinical Research and Development at CSL Behring/CSL Limited. During his time at CSL, he was responsible for globalising CSLs Clinical Research and Development group and for conception and execution of CSLs clinical trial strategies across a broad range of therapeutic areas from Phase 1 to commercialisation. He was a founding member of CSL Seqirus executive leadership team in 2015 as SVP of Research and Development until his retirement in April 2022.

-

-